Adherex Technologies Inc.
FENC Healthcare Biotechnology
Adherex Technologies Inc.’s revenue for fiscal 2025 (year ended December 2025) was $44.6 million, down 6.09% from fiscal 2024. In the quarter to June 2026, revenue grew 85.2%, EPS grew 154.6% and free cash flow grew 101.4%, each against the same quarter a year earlier.
Follow FENC
Adherex Technologies Inc. (FENC) EV/Sales
As of 16 October 2026, Adherex Technologies Inc. (FENC) trades at a EV/Sales of 5.4×. Over the past ten years it has ranged from 0.0× (June 2023) to 36.8× (July 2023); the current reading is higher than 85% of that period. That is below the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 4.5× | 30.76% |
| FY2024 | 3.5× | (76.47%) |
| FY2023 | 14.7× | — |
| FY2022 | 0.0× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 5.9× | 58.49% |
| Mar 2026 | 3.7× | (17.79%) |
| Dec 2025 | 4.5× | (31.96%) |
| Sep 2025 | 6.6× | (3.59%) |
| 12 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| TTRX Turn Therapeutics Inc. compare | n/m |
| KYTX Kyverna Therapeutics, Inc. compare | n/m |
| RZLT Rezolute, Inc. compare | n/m |
| GALT Galectin Therapeutics Inc. compare | n/m |
| AVIR Atea Pharmaceuticals, Inc. compare | 0.4× |
| EDIT Editas Medicine, Inc. compare | 2.2× |
| CCCC C4 Therapeutics, Inc. compare | 3.6× |
| FENC Adherex Technologies Inc. | 5.4× |
| OBIO Orchestra BioMed Holdings, Inc. compare | 8.5× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)